Recommended Products
form
liquid
Quality Level
shelf life
1 yr
manufacturer/tradename
Cell Applications, Inc
shipped in
dry ice
storage temp.
−20°C
Related Categories
General description
Added to Basal Medium to create Growth Medium
Human endothelial cell growth supplement is added to the basal medium to create growth medium. The complete growth medium (equivalent to Cat# 211-500) is optimized and best-suited for angiogenesis and other physiological studies.
Application
Endothelial Cell Growth Supplement (15ml) has been used as a supplement for culturing:
- human type II alveolar cells
- human umbilical vein endothelial cells (HUVEC)
- human pulmonary artery endothelial cells (HPAECs)
Quality
Each lot was tested for the ability to support plating, spreading and proliferation
Preparation Note
contained in protocol
WGK
WGK 3
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Michelle V Mouritzen et al.
Journal of peptide science : an official publication of the European Peptide Society, 24(7), e3093-e3093 (2018-06-26)
Neurotensin, substance P, and insulin have been demonstrated to improve wound healing in vivo. However, the mechanism behind their effect is still not fully understood. This study investigates the effects leading to enhanced scratch closure by these peptides in vitro.
Koustav Ganguly et al.
Scientific reports, 10(1), 20460-20460 (2020-11-26)
Limited toxicity data on electronic cigarette (ECIG) impede evidence-based policy recommendations. We compared two popular mixed fruit flavored ECIG-liquids with and without nicotine aerosolized at 40 W (E-smoke) with respect to particle number concentrations, chemical composition, and response on physiologically relevant
Hong Xue et al.
International journal of chronic obstructive pulmonary disease, 16, 1329-1345 (2021-05-20)
Etanercept (ETN), a tumor necrosis factor-α (TNF-α) inhibitor, has been applied in the treatment of many diseases. However, whether it has effects on chronic obstructive pulmonary disease (COPD) and its interaction with tumor necrosis factor receptor 1 (TNFR1) remained unknown.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service